Expression and clinical significance of tumor markers in ovarian mature cystic teratoma.
BACKGROUND
CA19-9, CA125, AFP, CEA, and CA153 are common cancer biomarkers. This study aimed to detect the expression and assess clinical significance of these biomarkers in ovarian mature cystic teratomas (OMCT).


METHODS
The clinical data of 312 resected patients with ovarian mature cystic teratoma referred to the third Hospital of Suzhou University from January 2008 to February 2014 were analyzed retrospectively. Levels of serum CA19-9, CA125, CA153, AFP, and CEA were detected.


RESULTS
Levels of serum CA19-9, CA125, AFP, and CEA were detected in all patients, but the level of serum CA153 was detected in 36 patients. The positive expression of these biomarkers above is 45.83%, 6.09%, 0.00%, 0.64%, and 2.78%, respectively. Ovarian tumor diameter in CA19-9 and CA 125 elevation is larger than that in negative group. The levels of serum CA19-9 and CA125 in multilocular ovarian tumor patients is higher than that in unilocular ovarian tumor patients. The level of serum CA19-9 in bilateral ovarian tumor patients is higher than that in unilateral patients. The level of CA19-9 in patients three months after operation decreased significantly compared with that before operation.


CONCLUSIONS
The present study suggests that elevated CA 19-9 is probably the most reliable marker among many tumor markers in the OMCT. It is valuable for diagnosis and recurrence of OMCT.
J M
JM
Chen
H Y
HY
Gao
Q
Q
Wang
Q
Q
Li
D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood*; D009378:Neoplasms, Multiple Primary / Q000097:blood* / Q000150:complications / Q000473:pathology; D010051:Ovarian Neoplasms / Q000097:blood* / Q000150:complications / Q000473:pathology; D012189:Retrospective Studies; D013724:Teratoma / Q000097:blood* / Q000150:complications / Q000473:pathology; D014102:Torsion Abnormality / Q000150:complications; D047368:Tumor Burden; D055815:Young Adult; D000509:alpha-Fetoproteins / Q000378:metabolism*
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D018396:Mucin-1; D000509:alpha-Fetoproteins